Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-36534 IRADIMED CORPORATION (Exact Name of Registrant As Specified In Its Charter) Delaware 73-1408526 (State or other jurisdictio ...

IRadimed Corporation (NASDAQ:IRMD) Q4 2021 Earnings Conference Call February 4, 2022 11:00 AM ET Company Participants Roger Susi – President and Chief Executive Officer Chris Scott – Chief Financial Officer Conference Call Participants Scott Henry – ROTH Capital Lisa Springer – Singular Research Operator Welcome to the IRadimed Corporation, Fourth Quarter 2021 Financial Results Conference Call. Currently, all participants are in a listen-only mode. And at the end of the call we will conduct a question-and-a ...

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended September 30, 2021 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 IRADIMED CORPORATION (Exact name of Registrant as specified in its charter) Delaware 73-1408526 (State or other j ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2021 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 IRADIMED CORPORATION (Exact name of Registrant as specified in its charter) Delaware 73-1408526 (State or other jurisd ...

IRadimed Corporation (NASDAQ:IRMD) Q2 2021 Earnings Conference Call July 30, 2021 11:00 AM ET Company Participants Roger Susi - President & Chief Executive Officer Chris Scott - Chief Financial Officer & Chief Operating Officer Conference Call Participants Scott Henry - ROTH Capital Lisa Springer - Singular Research Operator Welcome to the IRadimed Corporation Second Quarter 2021 Financial Results Conference Call. Currently, all participants are in a listen-only mode. And at the end of the call, we’ll condu ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended March 31, 2021 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 IRADIMED CORPORATION (Exact name of Registrant as specified in its charter) (State or other jurisdiction of incorpora ...

IRadimed Corporation (NASDAQ:IRMD) Q1 2021 Earnings Conference Call April 30, 2021 11:00 AM ET Company Participants Roger Susi – President and Chief Executive Officer Chris Scott – Chief Financial Officer Conference Call Participants Scott Henry – ROTH Capital Lisa Springer – Singular Research Operator Welcome to the IRadimed Corporation’s First Quarter 2021 Financial Results Conference Call. [Operator Instructions] As a reminder, this call is being recorded today, April 30, 2021, and contains time-sensitiv ...

Investor Presentation March 2021 Forward-Looking Statements Except for historical facts, the statements in this presentation, as well as oral statements or other written statements made or to be made by IRADIMED CORPORATION (the "Company"), are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 and involve risks and uncertainties. These statements relate to future events or our future financial performance or condition and involve unknown risks, uncertainti ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ⌧ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED DECEMBER 31, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO COMMISSION FILE NO. 001-36534 IRADIMED CORPORATION (Exact Name of Registrant As Specified In Its Charter) (State or other jurisdiction of incorporation o ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ⌧ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 1025 Willa Springs Drive Winter Springs, Florida 32708 (Address of principal executive offices) (Zip Code) For the Quarterly Period Ended September 30, 2020 OR ◻ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No.: 001-36534 IRADIM ...